Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

APPY 3.59 +0.03 (0.84%)
price chart
Broker Outlook For Venaxis, Inc. (APPY)
Venaxis, Inc. (Venaxis) is an in vitro diagnostic company that is focused on commercializing its blood-based test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children, adolescent and young adults.
Venaxis Inc. APPY (US: Nasdaq)
News Venaxis Inc.APPY. No news for APPY in the past two years. Key Stock Data ? P/E Ratio (TTM): The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted ...
Stocks to Keep Your Eyes on Neothetics Inc (NASDAQ:NEOT), Venaxis Inc (NASDAQ ...
Shares of Neothetics Inc (NASDAQ:NEOT) flew +14.58% to $1.20 at 2:06 PM EDT. The stock attained the volume of 2.06 Million shares recently versus average trading volume of 793,682.00 shares.
Venaxis, Inc. (APPY) Broker Price Targets For The Coming Week
Venaxis, Inc. (Venaxis) is an in vitro diagnostic company that is focused on commercializing its blood-based test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children, adolescent and young adults.
Venaxis, Inc. (NASDAQ:APPY) Consolidated Diluted EPS At $-2.2607  Equities Focus
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By Glancy ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of a class (the “Class”) comprising purchasers of the securities ...
Venaxis Inc (NASDAQ:APPY) fell 18.06% last Trade
By looking at Venaxis Inc (NASDAQ:APPY) YTD (year to date) performance, the stock shows Positive value of 1092.12%. If the YTD value is Negative, it means that the stock is trading poorly.
Incontact Inc, Andersons Inc, MacroGenics Inc, MGT Capital Investments Inc ...  Bidness ETC
Venaxis Jumps 20% On MGT Capital Investments' Stake (NASDAQ:APPY)  Sonoran Weekly Review
Venaxis Inc (APPY) Stock Crashes On FDA's “Not Substantially Equivalent” Response
Venaxis Inc (NASDAQ:APPY) has received "not substantially equivalent" remarks on its blood-based diagnostic test, APPY1, from the US Food and Drug Administration (FDA).
Venaxis Receives FDA "Not Substantially Equivalent" Response on ...  PR Newswire (press release)
Noble Equity Capital Management Issues Letter To Venaxis Shareholders
Given that the stock of Venaxis is trading at a 60% discount to its tangible book value, we find the announced merger with Strand to be value destructive for shareholders.
Venaxis, Inc. (NASDAQ:APPY) Consolidated Diluted EPS Stands At $-2.2607
Venaxis, Inc. (NASDAQ:APPY) produced $-2.2607 in basic EPS from continuing operations for the annual period ended 2015-12-31.
Analyst Coverage: Venaxis, Inc. (APPY)
Recently stock market analysts have updated their consensus ratings on shares of Venaxis, Inc. (APPY). The latest broker reports which are currently outstanding on Monday 6th of June state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...